← Back to Screener
NRX Pharmaceuticals, Inc. Warrant (NRXPW)
Price$0.00
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-109.24%
Price vs S&P 500 (4W)-62.99%
VGM Score0.55
All Metrics
Price vs S&P 500 (YTD)-103.76%
10-Day Avg Trading Volume0.06M
3-Month Avg Trading Volume0.03M
52-Week High$0.18
26-Week Price Return-98.27%
13-Week Price Return-93.50%
3-Month Return Std Dev541.91%
Year-to-Date Return-96.33%
5-Day Price Return-69.41%
Month-to-Date Return-81.82%
Price vs S&P 500 (13W)-101.65%
Beta1.26x
52-Week Low$0.00
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRXPWNRX Pharmaceuticals, Inc. Warrant | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
NRX Pharmaceuticals develops novel therapies for central nervous system disorders and critical pulmonary diseases. The company commercialized ZYESAMI (Aviptadil) for COVID-19-related respiratory failure and is advancing NRX-100/101 to treat bipolar depression with acute suicidal ideation. Its pipeline addresses significant unmet medical needs in high-acuity, underserved patient populations.